Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML. Ritchie EK, Cella D, Fabbiano F, Pigneux A, et al. Leuk Lymphoma 2023;64:938-950.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ritchie EK, Cella D, Fabbiano F, Pigneux A, et al. Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML. Leuk Lymphoma 2023;64:938-950.
PMID: 37019445